Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients
Abstract Limited data exists on SARS-CoV-2 sustained-response to vaccine in patients with rheumatic diseases. This study aims to evaluate neutralizing antibodies (nAB) induced by SARS-CoV-2 vaccine after 3 to 6 months from administration in Systemic Lupus Erythematosus (SLE) patients, as a surrogate...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-08-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-18996-x |
| _version_ | 1798004427789959168 |
|---|---|
| author | Silvia Garcia-Cirera Joan Calvet Antoni Berenguer-Llergo Edwards Pradenas Silvia Marfil Marta Massanella Lourdes Mateu Benjamin Trinité Maria Llop Marta Arévalo Carlos Galisteo Cristóbal Orellana Rafael Gómez María Nieves Gómez-Gerique Inma Carmona Bonaventura Clotet Julià Blanco Jordi Gratacós |
| author_facet | Silvia Garcia-Cirera Joan Calvet Antoni Berenguer-Llergo Edwards Pradenas Silvia Marfil Marta Massanella Lourdes Mateu Benjamin Trinité Maria Llop Marta Arévalo Carlos Galisteo Cristóbal Orellana Rafael Gómez María Nieves Gómez-Gerique Inma Carmona Bonaventura Clotet Julià Blanco Jordi Gratacós |
| author_sort | Silvia Garcia-Cirera |
| collection | DOAJ |
| description | Abstract Limited data exists on SARS-CoV-2 sustained-response to vaccine in patients with rheumatic diseases. This study aims to evaluate neutralizing antibodies (nAB) induced by SARS-CoV-2 vaccine after 3 to 6 months from administration in Systemic Lupus Erythematosus (SLE) patients, as a surrogate of sustained-immunological response. This cross-sectional study compared nAB titre of 39 SLE patients and 37 Healthy individuals with no previous SARS-CoV-2 infection, who had all received a complete regimen of a mRNA SARS-CoV-2 vaccine within the last 3 to 6 months. We included four lines of SLE treatment including Not-treated, Hydroxychloroquine, immunosuppressive drugs and biological therapy. Glucocorticoids were allowed in all groups. Healthy and Not-treated individuals showed the highest levels of nAB. Treated patients presented lower nAB titres compared to Healthy: a 73% decrease for First-Line patients, 56% for Second-Line treatment and 72% for Third-Line. A multivariate analysis pointed to Glucocorticoids as the most associated factor with declining nAB levels (75% decrease) in treated SLE. Furthermore, a significant reduction in nAB titres was observed for Rituximab-users compared to Healthy subjects (89% decrease). Medium-term response of SLE patients to SARS-CoV-2 mRNA vaccines is negatively impacted in Glucocorticoids and Rituximab users. These findings might help to inform recommendations in vaccination protocols for SLE patients. |
| first_indexed | 2024-04-11T12:23:32Z |
| format | Article |
| id | doaj.art-4e0f7fe7af794e2382f8fe911f0bbf38 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T12:23:32Z |
| publishDate | 2022-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-4e0f7fe7af794e2382f8fe911f0bbf382022-12-22T04:24:01ZengNature PortfolioScientific Reports2045-23222022-08-011211910.1038/s41598-022-18996-xGlucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patientsSilvia Garcia-Cirera0Joan Calvet1Antoni Berenguer-Llergo2Edwards Pradenas3Silvia Marfil4Marta Massanella5Lourdes Mateu6Benjamin Trinité7Maria Llop8Marta Arévalo9Carlos Galisteo10Cristóbal Orellana11Rafael Gómez12María Nieves Gómez-Gerique13Inma Carmona14Bonaventura Clotet15Julià Blanco16Jordi Gratacós17Rheumatology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT)Rheumatology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT)Biostatistics and Bioinformatics Rheumatology Department, Institut d’Investigació i Innovació Parc Taulí (I3PT)IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP)IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP)IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP)IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP)IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP)Rheumatology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT)Rheumatology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT)Rheumatology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT)Rheumatology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT)Rheumatology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT)Laboratory Technician at Research Unit, Institut d’Investigació i Innovació Parc Taulí (I3PT)Laboratory Technician at Research Unit, Institut d’Investigació i Innovació Parc Taulí (I3PT)IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP)IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP)Rheumatology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT)Abstract Limited data exists on SARS-CoV-2 sustained-response to vaccine in patients with rheumatic diseases. This study aims to evaluate neutralizing antibodies (nAB) induced by SARS-CoV-2 vaccine after 3 to 6 months from administration in Systemic Lupus Erythematosus (SLE) patients, as a surrogate of sustained-immunological response. This cross-sectional study compared nAB titre of 39 SLE patients and 37 Healthy individuals with no previous SARS-CoV-2 infection, who had all received a complete regimen of a mRNA SARS-CoV-2 vaccine within the last 3 to 6 months. We included four lines of SLE treatment including Not-treated, Hydroxychloroquine, immunosuppressive drugs and biological therapy. Glucocorticoids were allowed in all groups. Healthy and Not-treated individuals showed the highest levels of nAB. Treated patients presented lower nAB titres compared to Healthy: a 73% decrease for First-Line patients, 56% for Second-Line treatment and 72% for Third-Line. A multivariate analysis pointed to Glucocorticoids as the most associated factor with declining nAB levels (75% decrease) in treated SLE. Furthermore, a significant reduction in nAB titres was observed for Rituximab-users compared to Healthy subjects (89% decrease). Medium-term response of SLE patients to SARS-CoV-2 mRNA vaccines is negatively impacted in Glucocorticoids and Rituximab users. These findings might help to inform recommendations in vaccination protocols for SLE patients.https://doi.org/10.1038/s41598-022-18996-x |
| spellingShingle | Silvia Garcia-Cirera Joan Calvet Antoni Berenguer-Llergo Edwards Pradenas Silvia Marfil Marta Massanella Lourdes Mateu Benjamin Trinité Maria Llop Marta Arévalo Carlos Galisteo Cristóbal Orellana Rafael Gómez María Nieves Gómez-Gerique Inma Carmona Bonaventura Clotet Julià Blanco Jordi Gratacós Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients Scientific Reports |
| title | Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients |
| title_full | Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients |
| title_fullStr | Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients |
| title_full_unstemmed | Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients |
| title_short | Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients |
| title_sort | glucocorticoids treatment impairs the medium term immunogenic response to sars cov 2 mrna vaccines in systemic lupus erythematosus patients |
| url | https://doi.org/10.1038/s41598-022-18996-x |
| work_keys_str_mv | AT silviagarciacirera glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT joancalvet glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT antoniberenguerllergo glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT edwardspradenas glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT silviamarfil glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT martamassanella glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT lourdesmateu glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT benjamintrinite glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT mariallop glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT martaarevalo glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT carlosgalisteo glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT cristobalorellana glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT rafaelgomez glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT marianievesgomezgerique glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT inmacarmona glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT bonaventuraclotet glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT juliablanco glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients AT jordigratacos glucocorticoidstreatmentimpairsthemediumtermimmunogenicresponsetosarscov2mrnavaccinesinsystemiclupuserythematosuspatients |